Hebei Medical University Fourth Hospital

This study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard treatment, those whose tumors shrink less than 40% will switch to a new drug combo (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is to se…

This study tests whether adding radiotherapy to a mix of immunotherapy (QL1706) and a targeted drug (bevacizumab) can shrink liver tumors enough to allow surgery. It involves 60 adults with liver cancer that cannot be removed surgically and has not spread. The goal is to see if t…

This study tests the drug olaparib in 30 women with advanced triple-negative breast cancer that has come back or spread. Unlike other studies, these patients do not have the usual BRCA gene mutations but have a different change (BRCA1 promoter methylation) that may make the cance…

This study tests a new drug (befotertinib) combined with radiation therapy for people with advanced lung cancer that has spread to a few spots (oligometastatic) and has a specific gene change (EGFR mutation). The goal is to see if this combination can delay cancer growth. About 8…

This study tests whether a liposomal (encapsulated) form of irinotecan combined with other drugs works better than standard irinotecan for people with metastatic colorectal cancer that has progressed after first-line treatment. About 408 adults aged 18-75 will be randomly assigne…

This study tests whether adding the drug enlonstobart to short-course radiotherapy and chemotherapy can help shrink tumors more effectively in people with a certain type of advanced rectal cancer (pMMR). About 128 adults will receive either the standard treatment or the new combi…

This study looks at 2,000 women with HER2-positive breast cancer who still had cancer after initial treatment and surgery. Researchers compare two different drug combinations given after surgery to see which one helps prevent the cancer from coming back over three years. The goal…